Navigation Links
Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
Date:12/21/2007

MALVERN, Pa., Dec. 21 /PRNewswire/ -- Solstice Neurosciences, Inc. ("Solstice") announced the appointment of Dennis L. Smith as President and Chief Executive Officer. He will also continue to serve as Chairman to its Board of Directors.

Mr. Smith brings unique specialty pharmaceutical industry experience and expertise to Solstice that will be invaluable in providing guidance, leadership, and strategies for growth as the company continues to broaden its product portfolio globally and map its strategy.

Mr. Smith has nearly 35 years of broad and global experience in the pharmaceutical industry and most recently served as President and Chief Executive Officer of INO Therapeutics LLC., a specialty pharmaceutical company with strengths in development, marketing, and sales of critical care drugs and drug/device combinations. Prior to INO, Mr. Smith spent 15 years with DuPont Pharmaceutical Company, where he served as President of U.S. Operations, Executive Vice President of Europe, and Vice President and General Manager in Canada, among numerous other positions at DuPont Pharmaceuticals and DuPont Merck. Mr. Smith was also employed in management positions at Baxter International and Sandoz Pharmaceuticals (now Novartis). Mr. Smith is a graduate of Michigan State University and the Lake Forest Graduate School of Business.

"I am excited to be joining Solstice at this time to work with the management team and the Board of Directors to help lead and guide our company's future strategic direction," said Mr. Smith.

About Solstice Neurosciences, Inc.

Founded in 2004, Solstice Neurosciences, Inc. is a biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty products. Solstice's first product, Myobloc(R) (Botulinum Toxin Type B) Injectable Solution, represents the only botulinum toxin type B currently available to physicians and patients. MYOBLOC is sold in the United States and approved in Canada. It is also distributed and sold in the EU as NeuroBloc. MYOBLOC is indicated for the treatment of patients with cervical dystonia (CD) to reduce the severity of abnormal head position and pain associated with CD. For more information about Solstice Neurosciences, Inc., visit http://www.solsticeneuro.com.

Myobloc(R) and NeuroBloc(R) are registered trademarks of Solstice Neurosciences, Inc.


'/>"/>
SOURCE Solstice Neurosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
2. Insmed Appoints Dennis M. Lanfear to Board Of Directors
3. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
4. AUDIO from Medialink and GlaxoSmithKline: Fiber Key in Managing Irritable Bowel Syndrome (IBS) Symptoms
5. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
6. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
7. KGI and Smith College Establish Leadership Forum for Women in Bioscience
8. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
9. Orchid Cellmark Appoints James F. Smith Chief Financial Officer
10. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
11. GlaxoSmithKline Consumer Healthcare Recommends Maintaining FDAS Current Two-Class Drug System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... The two ... healthcare treatment options for patients. Vironika, a spin out from The Wistar Institute, and ... taking lab space at 3624 Market Street. , Vironika is developing a treatment ...
(Date:1/20/2017)... January 20, 2017 http://www.Financialbuzz.com ... one of leading causes of death worldwide. There were ... number of cancer related deaths increased gradually over time, ... incidence rate of various cancers continues to drive demand ... report by Global Market Insights, Inc. cancer biological therapy ...
(Date:1/19/2017)... 19, 2017  Market Research Future has a half cooked research ... Biopsy is growing rapidly and expected to reach USD 450 Million ... ... Biopsy Market has been assessed as a swiftly growing market and ... in the coming future. There has been a tremendous growth in ...
(Date:1/19/2017)... Jan 19, 2017 Research and Markets ... has announced the addition of the ... - Forecast to 2025" report to their offering. ... The report provides a detailed analysis on current and future market ... 2025, using estimated market values as the base numbers ...
Breaking Biology Technology:
(Date:12/19/2016)... España y TORONTO , 19 de diciembre de ... Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo ... varios tipos de tumor en 2017, con múltiples sitios previstos a ... ... con objetivo en el factor inhibidor de leucemia (LIF), una citoquina ...
(Date:12/16/2016)... 2016 Research and Markets has announced the ... Forecast to 2021" report to their offering. ... The biometric vehicle access system ... CAGR of 14.06% from 2016 to 2021. The market is estimated ... reach 854.8 Million by 2021. The growth of the biometric vehicle ...
(Date:12/15/2016)... Germany , December 15, 2016 ... announced an agreement with NuData Security, an award-winning ... partnership will enable clients to focus on good customer experience, ... protection regulation. ... In order to provide a one-stop fraud prevention suite, ...
Breaking Biology News(10 mins):